GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches.

Verhoeven, Marjolein; Ruigrok, Eline A M; van Leenders, Geert J L H; van den Brink, Lilian; Balcioglu, Hayri E; van Weerden, Wytske M; Dalm, Simone U

Verhoeven, Marjolein; Ruigrok, Eline A M; van Leenders, Geert J L H; van den Brink, Lilian; Balcioglu, Hayri E; van Weerden, Wytske M; Dalm, Simone U.

Afiliação

Verhoeven M; Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Ruigrok EAM; Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
van Leenders GJLH; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
van den Brink L; Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Balcioglu HE; Department of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
van Weerden WM; Department of Experimental Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Dalm SU; Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.

Front Oncol ; 13: 1199432, 2023.

Article em En | MEDLINE | ID: mdl-37719014

Palavras-chave

NeoB; PSMA-617; gastrin-releasing peptide receptor (GRPR); prostate cancer; prostate-specific membrane antigen (PSMA)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google